In 2022, JCR Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
JCR Pharmaceuticals has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2022 | 2021 |
|---|---|---|
Total Scope 1 | 3,315a | 2,232a |
Total Scope 2 | ||
Market-Based | 5,266a | N/A |
Location-Based | 7,670a | N/A |
Unspecified Calculation Method | N/A | 5,136a |
Total Scope 3 | 79,466a | 78,168a |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 7.9186a | 8.1835a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2022, the total operational greenhouse gas (GHG) emissions of JCR Pharmaceuticals amounted to 10,985 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2021, the total operational greenhouse gas (GHG) emissions of JCR Pharmaceuticals increased by 49.09%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2022, the total Scope 1 emissions of JCR Pharmaceuticals were 3,315 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2021), JCR Pharmaceuticals's Scope 1 emissions increased by 48.52%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2022, JCR Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 5,266 tCO₂e using the market-based method and 7,670 tCO₂e using the location-based method.a
In 2022, JCR Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2022, JCR Pharmaceuticals reported 79,466 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2022 disclosure of JCR Pharmaceuticals includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2021, reflecting improved emissions accounting practices and greater transparency across the company's value chaina
In 2022, JCR Pharmaceuticals reported total Scope 3 emissions of 79,466 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2021), JCR Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that JCR Pharmaceuticals's emissions have plateaued with no significant change in its value chain footprint.a
In 2022, JCR Pharmaceuticals reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2022, the largest contributors to JCR Pharmaceuticals's Scope 3 emissions were:a
In 2022, JCR Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 3,315 tCO₂e and total revenues of USD 419 millions. This translates into an emissions intensity of 7.92 tCO₂e per millions USD.a
In 2022, JCR Pharmaceuticals reported a Scope 1 emissions intensity of 7.92 tCO₂e per millions USD. Compared to the peer group median of 4.98, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2022, JCR Pharmaceuticals ranked 15 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
JCR Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2022, JCR Pharmaceuticals reported a total carbon footprint of 90,451 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.75% increase compared to 2021, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to JCR Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 87.86% of the company's total carbon footprint, followed by Scope 2 emissions at 8.48%.a